https://www.selleckchem.com/pr....oducts/Roscovitine.h
In a complete case analysis, mean dyspnea IPOS scores significantly decreased from 2.9 (standard error=0.1) to 1.5 (0.1) in the algorithm group (n=54; P 0.001), and 2.9 (0.1) to 1.6 (0.1) in the non-algorithm group (n=72; P 0.001). There was no significant between-group difference in changes in dyspnea IPOS scores (P=0.65). Adverse events were rare (n=5). The algorithm-based treatment was feasible, and might be as effective and safe as the usual care by palliative care specialists. Its implementation may help physicians pr
Like
Comment
Share
